Navigation Links
Anthera Announces Third Quarter 2010 Financial Report and Conference Call
Date:10/26/2010

HAYWARD, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2010 financial report after market close on Tuesday, November 2, 2010.  Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.Conference Call Access:Date:

November 2, 2010Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

19111226To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291.  The conference ID for the replay is 19111226. The audio replay will be available until November 9, 2010.  This conference call will be webcast live and archived on Anthera's website until November 2, 2011, www.anthera.com.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BAFF, which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017 The Global ... of around 8.2% over the next decade to reach ... trends that the market is witnessing include rapidly growing ... recent technological advancements in nebulizer products and online marketing ... type the market is categorized into pneumatic nebulizers, ultrasonic ...
(Date:1/17/2017)... Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... been enrolled in a Phase 3 clinical trial comparing ... care (BSC) in the prevention of hepatic veno-occlusive disease ... cell transplant (HSCT) who are at high risk or ... clinical trial will be conducted across approximately 100 medical ...
(Date:1/17/2017)... According to a new market research report "Neural Network Software Market by Type (Data ... - Global Forecast to 2021" published by MarketsandMarkets, the market to expand from ... Compound Annual Growth Rate (CAGR) of 33.2%. Continue ... ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased ... network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves ... exciting addition to our provider network, and the addition will benefit our members ...
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, ... Sigfox in the U.S.A. to offer Internet of Things (IoT) solutions based ... large-scale environmental sensor deployments such as monitoring solutions used to detect potentially hazardous ...
(Date:1/17/2017)... Baltimore, MD (PRWEB) , ... January 17, 2017 , ... ... joined the firm as a Principal in its IT Advisory Services practice . ... in recent months as market demand for strategic IT guidance grows, and the practice ...
(Date:1/17/2017)... ... 17, 2017 , ... Physicians Education Review®, LCC (PER®) announces ... for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at ... Talamo, said, “We are delighted to have Sandra Lee join us as our ...
(Date:1/17/2017)... ... , ... Many people make New Year’s resolutions or renew their commitment to better health with ... for people who want to kick off 2017 with better smiles. Dr. Mondavi is offering ... special offers include: , , A new patient package for just ...
Breaking Medicine News(10 mins):